Beyond Weight Loss: GLP-1 Drugs Target Heart Failure, Kidney Disease, and Addiction
The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.